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Recessive mutations in the MSTO1 gene, encoding for a mitochondrial distribution 
and morphology regulator, have been recently described in a very limited number of 
patients with multisystem involvement, mostly characterized by myopathy or 
dystrophy, cerebellar ataxia, pigmentary retinopathy and raised creatine kinase 
levels. Here we report an additional patient with recessive MSTO1-related muscular 
dystrophy (MSTO1-RD), and clinical and radiological evidence of progressive 
cerebellar involvement. Whole-exome sequencing identified two novel MSTO1 
missense variants, c.766C > T (p. (Arg256Trp)  and c.1435C > T (p. (Pro479Ser), 
predicted as damaging by in silico tools.  We also report a distinct pattern of 
selective involvement on muscle MRI in MSTO1-RD. This case confirms a consistent 
MSTO1-related neuromuscular phenotype and in addition suggests progressive 
neurological component at least in some patients, in keeping with the mitochondrial 
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Introduction 
Congenital muscular dystrophies (CMDs) and congenital myopathies (CMs) are 
individually rare and highly heterogeneous conditions, characterized by 
congenital/early onset muscle weakness and characteristic muscle biopsy findings 
compatible with a dystrophic or myopathic process, respectively. The clinical 
complexity of CMDs and CMs is mirrored by their wide genetic heterogeneity. With 
advances in novel diagnostic genetic technologies such as the introduction of next 
generation sequencing (NGS), the number of genes and disease-causing variants 
associated with CMDs and CMs has rapidly increased in recent years [1].  NGS and in 
particular whole exome (WES) or whole genome sequencing (WGS) are also 
facilitating diagnosis in patients with less distinguished phenotypes.  
Recessive mutations in the MSTO1 gene, located at 1q22 and encoding for an 
evolutionarily conserved, ubiquitously expressed cytoplasmatic protein with a key 
role in modulating mitochondrial dynamics, have been recently reported in 5 
patients from four unrelated families [2,  4]. The phenotype in these individuals was 
characterized by growth and motor delay, muscle weakness with raised creatine 
kinase (CK) levels, cerebellar hypoplasia and early-onset ataxia, and a pigmentary 
retinopathy. Muscle histopathology showed dystrophic features in 2 out of 3 
patients, and milder myopathic changes in the remaining case [4].  
Here, we report an additional patient with early-onset MSTO1-related muscular 
dystrophy, presenting with global developmental delay, proximal weakness, 
scoliosis, clinical and radiological evidence of cerebellar involvement and mild 
intellectual disability, further expanding the clinico-pathological spectrum of this 
recently described neuromuscular disorder. 
Case Report 
Clinical history:  
The patient, a 13-year-old boy of non-consanguineous Caucasian parents, was born 
at 42+2 weeks gestation by normal vaginal delivery following an uneventful 
pregnancy. He was floppy at birth and required facial oxygen due to the umbilical 
cord being tightly wrapped around his neck. During the early postnatal period, he 
showed no feeding and breathing problems, had normal antigravity movements and 
no gross hypotonia. He sat at 11 months of age and started walking at 2 years of age. 
Scoliosis was first noted at around 2 years of age.  Speech development was slower 
compared to his peers, and he had persistent articulation problems for which he 
received speech language therapy. Family history was negative for neurological or 
neuromuscular disease.  
The patient was first seen in a specialized neuromuscular clinic at age 5 years. He 
was ambulant, but unable to run or climb up stairs. He showed a mild thoracolumbar 
scoliosis convex to the left. He had no symptoms or signs of bulbar or respiratory 
involvement. From the age of 8 years he started to show slow deterioration due to a 
combination of progressive muscle weakness and cerebellar involvement, becoming 
increasingly reliant on a wheelchair for longer distances. Additional neurological 
signs including dysarthria and intention tremor became obvious from the age of 10 
years, and he subsequently also developed progressive upper motor neuron signs 
including brisk reflexes, sustained clonus and upgoing plantars. At the age of 12 
years and 7 months, he was able to walk short distances indoors only, had frequent 
falls and difficulties getting up from the floor independently. He showed 
predominant proximal hip girdle weakness (hip flexors, abductors and adductors 
MRC 3; hip extension MRC 3-) with relatively better preserved strength in the 
shoulder girdle (shoulder abductors MRC4, shoulder flexor and extensors MRC3). His 
functional difficulties were disproportionate to the degree of muscle weakness on 
formal MRC grading.  He showed progressive tendon Achilles (TA) tightness for 
which ankle splints were provided.  There were no other contractures. The scoliosis 
remained stable under conservative management with a spinal brace and regular 
orthopedic surgical follow-up from 8 years of age. He frequently complained of 
muscle pain, but had no episodes of overt rhabdomyolysis. Speech became 
increasingly dysarthric over the years. Over time, mild to moderate behavioral and 
learning difficulties became more obvious, but there was no clear evidence of 
neuropsychological regression. He also had recurrent problems with bowel and 
bladder incontinence for which no underlying cause could be identified.  
On examination at age 13 years 7 months (Figure 1), weight was 43.94kg (>25th 
centile) and height was 145.70cm (>2nd centile), respectively. BMI was 20.7 kg. The 
patient showed no gross facial weakness and no ptosis. Range of extraocular 
movements was normal. He was able to stand on his toes, heels and on one leg but 
with difficulties only. He was unable to jump or hop. He got up from floor with a 
positive Gowers’ sign. He showed axial and proximal weakness, with mild asymmetry 
and more prominent in the lower limbs, with hip extensors on the left being the 
weakest muscles at MRC 2. Other MRC grades were as follows: neck and trunk 
flexors 3 and 3-, neck and trunk extensors 5 and 3+, shoulder flexors and extensors 3 
and 3-, shoulder abductors and adductors 3+ and 3, elbow flexors 4 and extensors 3 
on the right and 3+ on the left, hip flexors 3 and extensors 3- on the right and 2 on 
the left, hip abductors and adductors 3-on the right and 3 on the left, knee flexors 3+ 
on the right and MRC4 on the left, knee extensors 5, ankle plantar flexors 4 on the 
right and 5 on the left, ankle dorsiflexors 5 on the right and 4 on the left. He had mild 
TA contractures of approximately 10-15° bilaterally, with good range of movements 
in other joints, and some mild laxity in hands and fingers. He showed a mild thoracic 
curve convex to the left, stable from previous assessment, also in keeping with a 
stable Cobb angle of around 44 degrees on spinal X-rays. 
He had marked dysarthria and a slight intention tremor, but no past pointing was 
noted. Deep tendon reflexes were brisk in both upper and lower limbs with extensor 
plantar responses and clonus bilaterally.  
Neuropsychology assessment: 
Formal neuropsychology assessment at the age of 13 years and 8 months included 
an assessment of intellectual functioning (WISC-V, Wechsler Intelligence Scales for 
Children, Fifth UK Edition), and measures of language, verbal episodic memory, 
attention, visuomotor skills and review of reported social communication difficulties. 
His overall intellectual ability was low, within the bottom 10% of the normal 
population, but just above the level of an intellectual disability (FSIQ<70).  His 
clearest deficits were in the language domain, with his verbal intellectual functioning 
score, performance on an expressive language task and an auditory verbal working 
memory test all in the impaired range. Sustained attention by contrast was good, 
consistent with behavioural observations. Although verbal learning was hampered 
by poor working memory, he did not show amnesic difficulties. His fine motor 
abilities and shape copying were poor but there were no visuospatial matching 
problems. Parental and school reports (indicating problems with social 
communication, behavior and making and maintaining friendships) were consistent 
with him having difficulties on the Autistic Spectrum and he scored above cut-off on 
the Social Communication Questionnaire. He attended a special educational support 
unit within a mainstream secondary school.  
Investigations: 
Baseline blood investigations including full blood count, liver function tests, bone 
and renal profile, were normal. Lactate levels were 0.7 (normal range 0.7-2.1 
mmol/L). Plasma CK levels ranged between 909 to 1614 IU/L. Cardiac assessment 
including cardiac ultrasound were normal at 6 and 13 years. Respiratory assessments 
including forced vital capacity and sleep studies have been normal. He had normal 
hearing and ophthalmology assessments, and his most recent ophthalmological 
examination at age 13 years showed no abnormalities, in particular no evidence of 
retinitis pigmentosa. 
EMG and nerve conductions studies at 6 years of age were normal.  
Brain MRI at age 5 years showed cerebellar atrophy (Figure 2A); when repeated at 
12 years of age, there was mild progression of cerebellar atrophy and additional 
supratentorial sulcal prominence suggestive of volume loss (Figure 2B).  
Muscle MRI obtained at 13 years of age (Figure 3, F-J) showed marked involvement of 
the glutei within the pelvis (F). There was diffuse involvement within the thigh (G-H) 
with relative sparing of the gracilis compared to the sartorius, and the adductor longus 
compared to the adductor magnus. In the lower leg, the peroneal group and the 
gastrocnemii were the most severely affected muscle group, with variable 
involvement of other anterior compartment muscles, and relative sparing of the 
soleus.  
We compared these findings to recently obtained muscle MRI findings in another 
previously published MSTO1-mutated patient (patient N.3, Table 1) [4]. The muscle 
MRI in this additional patient revealed a recognizable pattern of selectivity, 
characterized by consistent involvement of sartorius, adductor magnus and the 
peroneal group, with relative sparing of gracilis, adductor longus and soleus, and 
variable involvement of other muscle groups.    
A muscle biopsy from the vastus lateralis performed at 6 years of age showed 
marked variability in fibre size across fascicles, with a dual fibre population of 
rounded and polygonal larger fibres surrounded by small fibres. There was striking 
fatty infiltration in between and focally within fascicles, with patchy fibrosis, and rare 
necrotic/regenerating fibres (Figure 4; A, C). Few fibres showed empty, mostly 
subsarcolemmal non-rimmed vacuoles without reinforcement of sarcolemmal 
proteins (Figure 4; B). There was an overall slow fibre predominance, and many 
larger fibres showed prominent central pallor with reduced mitochondrial staining 
(Figure 4; D). There was no (immune)histochemical evidence of mitochondrial 
Complex I/Complex IV deficiency. Several fetal myosin-positive fibres of all sizes and 
intensities were present (Figure 4; E). Overall, the picture was in keeping with a 
chronic, moderately severe muscular dystrophy. Initially, testing with a 
comprehensive immunopanel of dystrophy-associated proteins showed no 
convincing abnormalities. Retrospective immunolabelling performed following 
genetic testing showed profound reduction of MSTO1 labeling in this biopsy (Figure 
4; G), as well as the biopsy of the previously reported patient with pathogenic 
MSTO1 variants (Figure 4; H). Respiratory chain enzyme studies were normal.  
Genetic analysis: 
Pathogenic variants in the DYSF, LMNA FKRP and ANO5 genes were excluded by 
Sanger sequencing.  Following appropriate parental consent, DNA of the patient was 
included into the BBMRI-LPC project. WES analysis was carried out in the National 
Center for Genomic Analysis (CNAG), Barcelona, Spain. Data analysis was performed 
using the RD-Connect Genome-Phenome Analysis Platform.  To identify disease-
causing variants we applied several filters such as variants’ frequency in Exome 
aggregation consortium (ExAC) and Genome aggregation database 
(http://gnomad.broadinstitute.org),  and assessed the pathogenicity of variants 
identified by in silico prediction programs (Polyphen2 
(http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org) and Mutation 
Taster (http://www.mutationtaster.org). Variants predicted to be pathogenic by at 
least two in silico tools were selected.  
The analysis revealed two missense variants in the MSTO1 gene. The first variant 
c.766C >T, p. (Arg256Trp), affecting a conserved residue in the tubulin domain of the 
protein, is reported in the gnomAD dataset with an allelic frequency of 0.00003, 
while the second, c.1435C >T p. (Pro479Ser), is novel. Both variants were predicted 
to be damaging by all in silico tools (SIFT, Polyphen2 and Mutation taster). Sanger 
sequencing validation confirmed the presence of both variants in the patient and 
showed that both parents were carriers of one heterozygous MSTO1 variant each, 
confirming these to be in trans in the patient.   
 
Discussion 
In this study, we report the sixth patient affected by a neuromuscular condition 
caused by recessive variants in the MSTO1 gene. We identified 2 novel MSTO1 
variants and have added to the phenotypical spectrum of this recently described 
clinical entity by providing details of the associated neurological and 
neuroradiological phenotype. In view of its considerable clinical heterogeneity, we 
suggest referring to this condition as MSTO1-related muscular dystrophy (or, for 
brevity, MSTO1-RD). 
Including the current patient, most recessive MSTO1-RD patients show onset during 
the first year of life with developmental delay; one patient presented in the neonatal 
period with congenital arthrogryposis. Growth impairment, axial and proximal 
weakness, scoliosis, gait disturbances, dysmetria and tremor were the most common 
features (Table 1). Speech articulation problems suggestive of cerebellar dysarthria 
and mild cognitive impairment as seen in our patient have been previously reported 
only in a few cases.  However, our patient was the first in whom upper motor signs 
and substantial clinical progression were noted, suggesting a more complex 
progressive neurological phenotype.  Pigmentary retinopathy was detected in 2 
previously reported patients at age 16 and 13 years, respectively, but was not 
present in our case at the same age.  Considering the possibility of variable onset, we 
cannot exclude a later occurrence of this complication in further individuals and thus 
recommend regular ophthalmic reviews for all MSTO1-RD patients. Dysmorphic 
features (triangular face, sunken eyes) and thick hair were reported in 3 previous 
cases but those were not prominent in our case. Of note, CK levels were elevated in 
all cases with recessive MSTO1-RD but levels were highly variable, ranging from 
between 430 up to 5420 U/l.   
Cerebellar hypotrophy was detected in all patients with recessive MSTO1-RD, with 
onset in early childhood [2, 4]; in one previous case, short term longitudinal 
neuroradiological features did not identify any progression.  Sequential brain MRI 
from the present case obtained at an interval of 7 years however indicated mild 
progression of cerebellar atrophy over time, corresponding to evolution of additional 
neurological, in particular cerebellar and upper motor neuron signs, over the same 
period (Figure 2).  
Muscle MRI features of MSTO1-RD have not been reported to date. Here we report a 
pattern of consistent selectivity also in comparison with recently obtained muscle 
MRI findings from a previously published patient (Figure 3). Also considering a 
degree of variability between patients, review of further cases is needed to further 
clarify this pattern. 
Muscle biopsy findings in MSTO1-RD have been reported variably as being 
myopathic or dystrophic, suggesting a spectrum of pathological severity. We noted 
similarities in the pathology of the present case and the previously reported patient 
from our centres, both showing an overall moderately dystrophic pattern with 
minimal active necrosis/regeneration, striking fatty infiltration and fibrosis, and a 
small number of fibres featuring non-rimmed vacuoles.  
MSTO1 labeling of frozen muscle sections utilizing a rabbit polyclonal MSTO1 
antibody (PA5-21641, Thermofisher) with the epitope mapping to a region between 
amino acids 34-347 of the protein was markedly reduced in our patient (Figure 4; G) 
and the previously reported case (Figure 4, H), and, interestingly, in a case of MICU1-
RD, compared to labeling of an unaffected control that produced a discernible 
mitochondrial staining pattern with subsarcolemmal accentuation (Figure 4, F). 
MSTO1 labeling was also retained in the two other disease controls; CHKB-RD (Figure 
4; J) and TK2-RD (Figure 4; K), in both cases, the abnormal distribution of MSTO1 
mirroring the mitochondrial staining. In view of these findings, MSTO1 
immunoanalysis could be helpful in directing molecular testing and/or interpretation 
of variants within the appropriate clinical context, bearing in mind that secondary 
changes of MSTO1 immunolabelling may be observed in non-MSTO1-RD. Further 
testing of this antibody in a variety of muscular dystrophies will be necessary to 
ascertain the prevalence of secondary abnormalities.   
MSTO1 (or Misato 1) is a soluble protein, predominantly localized in the cytoplasm. 
The function of Misato1 is not yet fully understood. Misato1 appears to interact with 
the outer mitochondrial membrane during fusion [3, 4,] and to be required for 
mitochondrial fusion and mitochondrial network formation [5, 6]. Recent data show 
a critical role of Misato1 in modulating mitochondrial dynamics by regulating 
mitochondrial morphology and distribution [4]. Of note, pathogenic variants in genes 
involved in mitochondrial fusion and fission have been associated with diverse 
genetic disorders with predominant neurological phenotypes suggesting that 
mitochondrial fission proteins are essential for cerebellar development [7]. For 
example, the mitochondrial fission protein Drp1 regulates mitochondrial transport 
and dendritic arborization in cerebellar Purkinje cells, and is required for cerebellar 
development [7]. Pathogenic variants in the DNM1L gene, encoding for DrP1, cause 
a lethal form of encephalopathy with defective mitochondrial and peroxisomal 
fission, characterized by features in part overlapping what observed in MSTO1-RD, 
such as in particular the predominant neurological and ophthalmic involvement [8]. 
Analysis of DNM1L mutated patient fibroblasts showed elongated, tangled 
mitochondria, with tubular structures in particular around the nuclei [8].  While the 
multisystem features of MSTO1-RD with muscular, cerebellar, ophthalmic and 
skeletal involvement is similar to what seen in other mitochondrial cytopathies, the 
normal lactate levels and respiratory chain enzyme values are not typical of primary 
mitochondrial OXPHOS diseases. In contrast to primary mitochondrial cytopathies, 
MSTO1-RD patients also show raised CK values, often markedly elevated in the 
region of 10-20x the normal values, and muscle imaging findings (Figure 3), in 
keeping with a diagnosis of a muscular dystrophy. Secondary mitochondrial 
dysfunction is not unique for MSTO1 gene related muscular dystrophies. For 
example, loss-of-function variants in the MICU1 gene have been associated with a 
progressive brain and muscle disorder, characterized by raised CK and dystrophic 
muscle pathology, with alterations in mitochondrial calcium signaling (Logan et al, 
2016).  Interestingly, a recent paper showed that the mitochondrial dysfunction in 
the mdx mouse model of DMD compromises the repair of injured myofibers, 
suggesting further role of mitochondria in membrane resealing and thus in muscle 
pathology in dystrophinopathies [9]. Further studies on MSTO1-RD will be necessary 
to fully clarify if altered mitochondrial dynamics contribute to this specific 
pathological process.  
Notably, Gal et al., [3] reported on a heterozygous variant in the MSTO1 gene 
segregating in affected members of a dominant family, presenting with an adult-
onset myopathy, distal involvement, hypoacusis, endocrine dysfunctions, psychiatric 
symptoms and normal CK. This phenotype appears different from what observed in 
recessive MSTO1-RD, suggesting that, if confirmed to be pathogenic, dominant 
MSTO1 gene variants could associate with a different clinical presentation. 
In conclusion, our report further expands the phenotypic and genetic knowledge 
concerning MSTO1-RD, in particular by reporting 2 novel pathogenic MSTO1 variants 
and by describing progression of neurological involvement, comprising progressive 
cerebellar but also additional upper motor neuron signs. In addition, for the first 
time we report muscle MRI features of this rare condition in 2 patients. Investigation 
of further patients will be important not only to further inform phenotype-genotype 
correlations, but also to provide a better understanding of the function of the 
protein and underlying disease mechanisms. In view of our findings, we strongly 
recommend investigating MSTO1 gene variants in patients presenting with early 
onset myopathies/muscular dystrophies with raised CK, in particular in cases with 
additional cerebellar involvement.  
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Figure 1:  Patient with MSTO1-related RD at 13 years of age 
 
Figure 2: Brain MRI findings in MSTO1-RD 
Brain MRI images obtained at 5 (A-C) and 12 (D-F) years of age, axial (A,D), sagittal 
(B,E) and coronal (C,F) sections. There is cerebellar atrophy with evidence of mild 
progression between the two scans.  
 
Figure 3: Muscle MRI findings in MSTO1-RD 
Muscle MRI images of the lower limb, T1-weighted images, transverse sections, from 
the patient reported in this paper obtained at 13 years of age (A-E), and from a 
previously reported male patient obtained at 7 years of age. Both patients show 
marked involvement of the glutei within the pelvis (A,F), with an overall more 
proximal pattern of involvement in the more mildly affected patient. Within the 
thigh (B-C;G-H), pattern of involvement was diffuse, with relative sparing of gracilis 
(G) compared to sartorius (S), and adductor longus (AL) compared to adductor 
magnus (AM) in both patients.  Quadriceps (in particular rectus femoris, RF) and 
hamstring muscles were more variably affected. Within the lower leg (D-E;I-J), the 
peroneal group (PG) was the most severely affected muscle group in both patients. 
In the more severely affected patient (on the right), there was additional 
involvement of other anterior compartment components and the gastrocnemii, with 
relative sparing of the soleus. VL = vastus lateralis; So = soleus; Gm = gastrocnemius 
medialis, Gl = gastrocnemius lateralis.    
 
Figure 4: Histopathological findings 
Vastus lateralis biopsy performed at 6 years of age. Haematoxylin and eosin stained 
sections show marked variability in fibre size across fascicles, with a dual fibre 
population of rounded and polygonal larger fibres surrounded by small fibres. There 
is striking fatty infiltration in between and focally within fascicles, with patchy 
fibrosis, and rare necrotic/regenerating fibres (A, C). Few fibres show empty, mostly 
subsarcolemmal non-rimmed vacuoles (B) without reinforcement of sarcolemmal 
proteins (B, inset). Many larger fibres show prominent central pallor with reduced 
mitochondrial staining in a section immunolabeled with an antibody to 
mitochondrial complex IV sub-unit MTCO1 (D). Several fetal myosin-positive fibres of 
all sizes and intensities are present (Figure Z; E). MSTO1 immunohistochemistry 
shows a discernible mitochondrial staining pattern in an unaffected control (F), with 
profound reduction of labeling in this patient (G), as well as the biopsy of the 
previously reported patient with pathogenic MSTO1 variants (H) and a case of 
MICU1-myopathy. Labeling is retained and mirrors the abnormal mitochondrial 
distribution pattern in a case of CHKB-muscular dystrophy (J) and TK2-myopathy (K) 
Scale bar (A-K): 100 µm       
 
 
Table 1. Phenotypic and genetic characteristics of current and reported patients 
with recessive MSTO1 -RD 
 
 
